Norethindrone
Mostrando 1-5 de 5 artigos, teses e dissertações.
-
1. Densidade mineral ossea em usuarias de contraceptivos injetaveis combinados
BACKGROUND: The objective of this study was to compare bone mineral density (BMD) between users of two kinds of once-a-month combined injectable contraceptives (CIC) and controls. SUBJECTS AND METHODS: This crosssectional study included 97 women of 20 to 45 years of age, using CIC containing either 25 mg of medroxyprogesterone acetate and 5 mg of estradiol c
Publicado em: 2006
-
2. "Avaliação do tratamento hormonal e/ou intervencionista por punção nos tumores císticos de ovários" / Evaluation of hormonal treatment and/or intervention through aspiration of ovarian cystic tumors
Objetivo: O objetivo deste estudo foi avaliar em mulheres com tumores císticos de ovário, a proporção que, somente com o tratamento clínico e/ou punção, não necessitaram de cirurgia; a influência da medicação e das doenças associadas na indicação de cirurgia e se a punção reduziu significativamente o tamanho dos cistos. Casuística e métodos
Publicado em: 2006
-
3. Estudo teorico das relações entre estrutura e atividade biologica : hormonios, esteroides e hidrocarbonetos policiclicos aromaticos
Using the PCILO rnethod, we studied which conformational factors were involved in the biological action of progesterone, corticosterone, cortisol and contraceptives - norethindrone, d-norgestrel, normethandrone and 17b-hidroxy-17-methylestra-4,15-dien-3-one. It was shown that the steroids in isolated state have generally similar conformations to observed one
Publicado em: 1981
-
4. In Vivo and In Vitro Action of Norethindrone on Staphylococci
Norethindrone has been examined in vitro for antibacterial activity against 10 microorganisms. Turbidimetric techniques were used to assay the antibacterial activity of norethindrone. The organisms tested included Staphylococcus aureus, S. epidermidis, Micrococcus conglomeratus, Listeria monocytogenes, Streptococcus faecalis, Salmonella typhosa, Shigella fle
-
5. The X-ray Structure of RU486 Bound to the Progesterone Receptor in a Destabilized Agonistic Conformation
Here we describe the 1.95 Å structure of the clinically used antiprogestin RU486 (mifepristone) in complex with the progesterone receptor (PR). The structure was obtained by taking a crystal of the PR ligand binding domain containing the agonist norethindrone and soaking it in a solution containing the antagonist RU486 for extended times. Clear ligand excha
American Society for Biochemistry and Molecular Biology.